Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | AMD1 | P17707 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19302804 | 0.91 | RXFP1 (0.59) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL19302803 | 0.87 | RXFP1 (0.51) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4896950 | 0.87 | PI4KA (0.54) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12379190 | 0.87 | PI4KA (0.54) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24450929 | 0.86 | RXFP1 (0.49) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29695854 | 0.86 | RXFP1 (0.49) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18571809 | 0.86 | PI4KA (0.62) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20699834 | 0.86 | PI4KA (0.62) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18069462 | 0.86 | PI4KA (0.52) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12379237 | 0.86 | PI4KA (0.62) | RXFP1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | Memorial Slooan-Kettering Cancer Center (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | RXFP1 3073/4885PI4KA 2340/4885PI4K2B 3618/4885 |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ATIC, SLC35B2, ADORA1 | RXFP1 3073/4885PI4KA 2340/4885PI4K2B 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.